1.49
+0(+0.00%)
Currency In USD
| Previous Close | 1.49 |
| Open | 1.46 |
| Day High | 1.52 |
| Day Low | 1.4 |
| 52-Week High | 6.4 |
| 52-Week Low | 0.77 |
| Volume | 106,493 |
| Average Volume | 248,522 |
| Market Cap | 22.29M |
| PE | -0.57 |
| EPS | -2.62 |
| Moving Average 50 Days | 1.55 |
| Moving Average 200 Days | 1.92 |
| Change | 0 |
If you invested $1000 in Longeveron Inc. (LGVN) since IPO date, it would be worth $20.11 as of May 09, 2025 at a share price of $1.49. Whereas If you bought $1000 worth of Longeveron Inc. (LGVN) shares 3 years ago, it would be worth $18.7 as of May 09, 2025 at a share price of $1.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
GlobeNewswire Inc.
May 02, 2025 12:30 PM GMT
MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it wi
Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025
GlobeNewswire Inc.
Apr 22, 2025 8:05 PM GMT
Wa'el Hashad Wa'el Hashad, CEO, Longeveron MIAMI, April 22, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic agi
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease
GlobeNewswire Inc.
Mar 20, 2025 1:00 PM GMT
Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer’s diseaseAlignment with FDA